|
Market Closed -
Nasdaq
00:00:00 31/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 927.89 USD | +13.33% |
|
+15.26% | +20.21% |
| 10-31 | US Equity Markets End Lower After Sell-Off in Technology Stocks | MT |
| 10-30 | Regeneron Pharmaceuticals, Inc. announces Quarterly dividend, payable on December 03, 2026 | CI |
Company Valuation: Regeneron Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 66,029 | 77,057 | 93,403 | 76,639 | 79,193 | 92,654 | - | - |
| Change | - | 16.7% | 21.21% | -17.95% | 3.33% | 17% | - | - |
| Enterprise Value (EV) 1 | 56,196 | 77,057 | 84,542 | 70,331 | 73,294 | 85,051 | 81,686 | 77,973 |
| Change | - | 37.12% | 9.71% | -16.81% | 4.21% | 16.04% | -3.96% | -4.55% |
| P/E | 8.77x | 18.9x | 25.3x | 18.6x | 18.6x | 19.2x | 17.8x | 15.9x |
| PBR | 3.56x | 3.41x | 3.64x | 2.62x | 2.58x | 2.76x | 2.41x | 2.12x |
| PEG | - | -0.4x | -2.8x | 1.8x | 2.27x | 1.2x | 2.31x | 1.3x |
| Capitalization / Revenue | 4.11x | 6.33x | 7.12x | 5.4x | 5.52x | 5.26x | 4.98x | 4.64x |
| EV / Revenue | 3.5x | 6.33x | 6.45x | 4.95x | 5.11x | 4.83x | 4.39x | 3.9x |
| EV / EBITDA | 5.71x | 12.7x | 15.2x | 12.3x | 13.5x | 10.6x | 9.89x | 8.56x |
| EV / EBIT | 6.28x | 13.5x | 16.5x | 13.5x | 15x | 12.5x | 11.2x | 9.44x |
| EV / FCF | 8.61x | 17.4x | 21.8x | 19.2x | 18x | 13.5x | 12.6x | 10.5x |
| FCF Yield | 11.6% | 5.74% | 4.58% | 5.21% | 5.57% | 7.39% | 7.97% | 9.56% |
| Dividend per Share 2 | - | - | - | - | 3.52 | 3.945 | 4.295 | 4.719 |
| Rate of return | - | - | - | - | 0.46% | 0.43% | 0.46% | 0.51% |
| EPS 2 | 71.97 | 38.22 | 34.77 | 38.34 | 41.48 | 48.35 | 52.07 | 58.43 |
| Distribution rate | - | - | - | - | 8.49% | 8.16% | 8.25% | 8.08% |
| Net sales 1 | 16,072 | 12,173 | 13,117 | 14,202 | 14,343 | 17,604 | 18,587 | 19,981 |
| EBITDA 1 | 9,835 | 6,060 | 5,547 | 5,695 | 5,428 | 8,024 | 8,259 | 9,112 |
| EBIT 1 | 8,947 | 5,719 | 5,126 | 5,212 | 4,884 | 6,817 | 7,302 | 8,262 |
| Net income 1 | 8,075 | 4,338 | 3,954 | 4,413 | 4,505 | 5,415 | 5,676 | 6,343 |
| Net Debt 1 | -9,833 | - | -8,862 | -6,308 | -5,899 | -7,603 | -10,968 | -14,682 |
| Reference price 2 | 631.52 | 721.49 | 878.29 | 712.33 | 771.87 | 927.89 | 927.89 | 927.89 |
| Nbr of stocks (in thousands) | 104,556 | 106,802 | 106,347 | 107,590 | 102,599 | 99,855 | - | - |
| Announcement Date | 04/02/22 | 03/02/23 | 02/02/24 | 04/02/25 | 30/01/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 19.19x | 4.83x | 10.6x | 0.43% | 92.65B | |
| 41.54x | 14.06x | 31.11x | 0.48% | 1,263B | |
| 39.99x | 6.71x | 18.89x | 1.95% | 658B | |
| 38.61x | 8.62x | 17.83x | 2.33% | 521B | |
| 21.74x | 5.27x | 13.12x | 2.48% | 391B | |
| 109.15x | 6.06x | 25.73x | 2.28% | 369B | |
| 23.19x | 5.97x | 14.41x | 2.71% | 307B | |
| 24.47x | 4.9x | 13.63x | 1.77% | 290B | |
| 29.56x | 7.53x | 13.48x | 2.16% | 252B | |
| -49.1x | 7.47x | 29.35x | 1.93% | 212B | |
| Average | 29.84x | 7.14x | 18.81x | 1.85% | 435.46B | |
| Weighted average by Cap. | 36.90x | 8.76x | 21.72x | 1.67% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- REGN Stock
- Valuation Regeneron Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
